851535-08-5Relevant academic research and scientific papers
Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate
Helal, Christopher J.,Arnold, Eric,Boyden, Tracey,Chang, Cheng,Chappie, Thomas A.,Fisher, Ethan,Hajos, Mihaly,Harms, John F.,Hoffman, William E.,Humphrey, John M.,Pandit, Jayvardhan,Kang, Zhijun,Kleiman, Robin J.,Kormos, Bethany L.,Lee, Che-Wah,Lu, Jiemin,Maklad, Noha,McDowell, Laura,McGinnis, Dina,O'Connor, Rebecca E.,O'Donnell, Christopher J.,Ogden, Adam,Piotrowski, Mary,Schmidt, Christopher J.,Seymour, Patricia A.,Ueno, Hirokazu,Vansell, Nichole,Verhoest, Patrick R.,Yang, Edward X.
, p. 1001 - 1018 (2018/02/17)
Computational modeling was used to direct the synthesis of analogs of previously reported phosphodiesterase 2A (PDE2A) inhibitor 1 with an imidazotriazine core to yield compounds of significantly enhanced potency. The analog PF-05180999 (30) was subsequen
Triazine Derivatives
-
Paragraph 0140, (2014/11/13)
The present invention is directed to a new class of triazine derivatives as described by formula I below in which A, X, R1, R2, R3, and R4 are as defined herein and to the use of the compounds as PDE10 inhibitors.
Imidazo[5,1-f][1,2,4]Triazines for the Treatment of Neurological Disorders
-
Page/Page column 21, (2012/09/05)
The present invention relates to compounds of the Formula and pharmaceutically acceptable salts thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds as a method for the treatment of a disease or condition selected from the group consisting of central nervous system disorders, cognitive disorders, schizophrenia, dementia and other disorders in a mammal.
